Effects of sustained GABA releasing implants on pancreatic islets in mice
Autor: | Edward A. Phelps, Jorge Santini-González, D. Walker Hagan, Kevin C Ling |
---|---|
Rok vydání: | 2021 |
Předmět: |
geography
geography.geographical_feature_category Chemistry Pancreatic islets Pharmaceutical Science 02 engineering and technology Pharmacology 021001 nanoscience & nanotechnology medicine.disease Islet 030226 pharmacology & pharmacy Alpha cell 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure nervous system Fibrosis In vivo Drug delivery medicine Implant Beta cell 0210 nano-technology |
Zdroj: | Drug Delivery and Translational Research. 11:2198-2208 |
ISSN: | 2190-3948 2190-393X |
DOI: | 10.1007/s13346-020-00886-2 |
Popis: | Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that is strongly and selectively synthesized in and secreted from pancreatic beta cells. Exogenously delivered GABA has been proposed to induce beta cell regeneration in type 1 diabetes, but these results have been difficult to replicate and may depend on the specifics of the animal model and drug delivery method used. Here, we developed a GABA-releasing ethylene-vinyl acetate polymer implant for sustained GABA delivery to the intraperitoneal space as an alternative to injected or oral GABA. We explored the effect of the GABA-releasing polymer implants compared to implanted osmotic pumps loaded with GABA on islet size in non-diabetic, outbred mice. We also attempted to monitor in vivo GABA release using HPLC on blood samples, but these measurements were confounded by high variability within treatment groups and unexpectedly high serum GABA levels in mice receiving GABA-negative implants. The ethylene-vinyl acetate polymer implants became heavily fibrosed with abdominal adhesion tissue, while the osmotic pumps had no macroscopic fibrosis. Histological analysis showed no significant effect of the sustained GABA delivery polymer or osmotic pumps on islet size, alpha cell to beta cell ratio, or the number of Ki67-positive islet cells. The GABA treatment time course was limited to two weeks due to the drug-release window of the polymer, while others reported islet-trophic effects of GABA after 10 to 12 weeks of treatment. In summary, our study is consistent with the concept that exogenous GABA administration does not significantly alter islet cell mass in non-diabetic CD-1 mice in the short-term. However, more data are needed including higher GABA doses and more prolonged treatment regimens for a better comparison with contrasting reports. |
Databáze: | OpenAIRE |
Externí odkaz: |